moomoo ID:NaN
Log Out
Log in to access Online Inquiry

ZIVO Bioscience (OTCMKTS:ZIVO) Share Price Crosses Below Fifty Day Moving Average of $3.65

Defense World ·  {{timeTz}}

ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating)'s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.65 and traded as low as $2.85. ZIVO Bioscience shares last traded at $3.02, with a volume of 6,150 shares.

ZIVO Bioscience Trading Down 0.3 %

The stock has a market capitalization of $28.45 million, a price-to-earnings ratio of -3.05 and a beta of -0.05. The firm has a 50-day moving average of $3.65 and a 200 day moving average of $3.56.

Get ZIVO Bioscience alerts:

ZIVO Bioscience (OTCMKTS:ZIVO – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter.

Insider Activity at ZIVO Bioscience

In other ZIVO Bioscience news, Director Christopher D. Maggiore bought 7,200 shares of the stock in a transaction that occurred on Wednesday, September 14th. The shares were purchased at an average cost of $3.53 per share, for a total transaction of $25,416.00. Following the transaction, the director now directly owns 810,305 shares in the company, valued at $2,860,376.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 17.10% of the stock is owned by insiders.

Hedge Funds Weigh In On ZIVO Bioscience

An institutional investor recently raised its position in ZIVO Bioscience stock. Vanguard Group Inc. raised its position in shares of ZIVO Bioscience, Inc. (OTCMKTS:ZIVO – Get Rating) by 19.6% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 92,468 shares of the biotechnology company's stock after purchasing an additional 15,147 shares during the quarter. Vanguard Group Inc. owned about 0.98% of ZIVO Bioscience worth $359,000 as of its most recent SEC filing. 5.04% of the stock is owned by institutional investors.

About ZIVO Bioscience

(Get Rating)

ZIVO Bioscience, Inc, a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health.

Featured Articles

  • Get a free copy of the StockNews.com research report on ZIVO Bioscience (ZIVO)
  • Defensive Stocks For A Volatile Market
  • SunPower Is Ready To Power Up Triple-Digit Earnings Gains
  • Will UPS Be Next to Deliver a Warning?
  • Is This the Darkest Before the Dawn for Gap Stock?
  • Build A Better Tech Portfolio With Jabil Inc.

Receive News & Ratings for ZIVO Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIVO Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.